

PHARMACEUTICAL 2022

KalVista Pharmaceuticals Inc. Rank 38 of 466









RealRate

PHARMACEUTICAL 2022

KalVista Pharmaceuticals Inc. Rank 38 of 466



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 198% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	264,264
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,774
Liabilities, Non-Current	5,046
Other Assets	5,958
Other Compr. Net Income	450
Other Expenses	0
Other Liabilities	0
Other Net Income	11,679
Other Revenues	0
Property and Equipment	1,791
Research and Development	41,286
Selling, General and Administrative Expense	16,637

Output Variable	Value in 1000 USD
Assets	272,013
Liabilities	14,820
Expenses	57,923
Revenues	0
Stockholders Equity	257,193
Net Income	-46,244
Comprehensive Net Income	-46,019
Economic Capital Ratio	276%

